- Optimer Pharma presented 9/27/11 at the JMP conference - click here for complete webcast calendar and links to my notes.
- More detailed company and pipeline info can be found on the OPTR research page.
- See my notes below-
- Dificid launch: $3.9m sales thru distributers in first 7 weeks
- most recent week - 39% of reorders were repeat orders
- lifecycle management - pursue CDAD prophylaxis, and looking at new formualtions - won't go into this further yet
- $68m US payments from Astellas by 6 months after EMEA decision (just received CHMP opinion so that should be in 2-3 months)
- cash balance is enough to sustain launch, potential to get to cash flow positive. Most hospital launches break-even in about 3 years and our goal is to do better than that but we need to be prepared to sustain for 3 yrs
- next potential partnership is Japan
- viropharm - has only about 5 sales reps, does not actively market vancocin, but product does $270m sales. But we don't see ourselves as going head to head against vancocin in market.
RSS Feed
